VANCOUVER, BC, April 10, 2023 /CNW/ – Mydecine Innovations Group Inc. (“Mydecine” or the “Company”) (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce that, in connection with its previously announced Common…

Source

Previous articleNuminus Launches new Clinic Licensing Platform, the Numinus Network, to Accelerate Expansion
Next articlePT404 – Clusterbusters: The Horrors of Cluster Headaches and the Miracle of Psilocybin